Skip to main content
. 2020 Jul 28;93:100595. doi: 10.1016/j.curtheres.2020.100595

Table 1.

Demographic and baseline clinical characteristics in the study's intention to treat (ITT) population.

Variable Rosuvastatin + Ezetimibe (n = 66) Simvastatin + Ezetimibe (n = 63) Total
(n = 129)
Demographic
Gender Female 55 (83.3%) 53 (84.1%) 108 (83.7%)
Male 11 (16.7%) 10 (15.9%) 21 (16.3%)
Age, mean (SD), y Mean (SD) 59.39 (8.7%) 59.16 (9.6%) 59.28 (9.1%)
Race White 51 (77.3%) 45 (71.4%) 96 (74.4%)
Non-white 15 (22.7%) 18 (28.5%) 33 (25.6%)
BMI, mean (SD), kg/m2 Overweight (25-30) 25 (37.9%) 25 (39.7%) 50 (38.8%)
Obesity (>30) 29 (43.9%) 25 (39.7%) 54 (41.9%)
Normal (<25) 12 (18.2%) 13 (20.6%) 25 (19.4%)
Medical history
Diagnosis Mixed dyslipidemia 26 (39.4%) 21 (33.3%) 47 (36.4%)
Primary hypercholesterolemia 40 (60.6%) 42 (66.7%) 82 (63.6%)
Tobacco use Never smoked/ex-smoker 55 (83.3%) 59 (93.7%) 114 (88.4%)
Smoker 11 (16.7%) 4 (6.3%) 15 (11.6%)
Comorbidities Controlled hypertension 37 (56.1%) 31 (49.2%) 68 (52.7%)
Uncontrolled hypertension 13 (19.7%) 11 (17.5%) 26 (20.2%)
Diabetes 23 (34.8%) 21 (33.3%) 44 (34.1%)
Ischemic heart disease 2 (3.0%) 2 (3.2%) 4 (3.1%)
Chronic kidney disease 0 (0.0%) 1 (1.6%) 1 (0.8%)
Metabolic syndrome 48 (72.7%) 38 (60.3%) 86 (66.7%)
Blood Pressure, mean (SD)
SBP (mmHg) 129,14 (15,64) 128,06 (15,82) 128,61 (15,68)
DBP (mmHg) 78,02 (10,13) 78,86 (9,02) 78,43 (9,58)
Lipid profiles, mean (SD)
HDL-C (mg/dL) 54,50 (12,20) 55,03 (10,29) 54,76 (11,27)
Non-HDL-C (mg/dL) 194,58 (33,32) 191,57 (27,16) 193,11 (30,39)
TC (mg/dL) 249,08 (34,72) 246,62 (29,00) 247,88 (31,95)
LDL-C (mg/dL) 163,62 (29,56) 160,89 (24,48) 162,29 (27,12)
TG (mg/dL) 154,71 (61,89) 148,49 (51,75) 151,67 (57,02)

SD = Standard Deviation; BMI = Body Mass Index; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; HDL-C = high density lipoprotein cholesterol; LDL-C = low density lipoprotein cholesterol; TC = Total Cholesterol; TG = Triglycerides